Targeting integrins αvβ3 and α5β1 with new β-lactam derivatives

European Journal of Medicinal Chemistry

Volumn 83, Issue , 2014, Pages 284-293

  Galletti, Paola ^a   Soldati, Roberto ^a   Pori, Matteo ^a   Durso, Margherita ^a   Tolomelli, Alessandra ^a   Gentilucci, Luca ^a   Dattoli, Samantha Deianira ^a   Baiula, Monica ^a   Spampinato, Santi ^a   Giacomini, Daria ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Agonists; Azetidinones; Cell adhesion; Integrins; Lactams; Peptidomimetics

Indexed keywords

(2 CARBOXY 4 OXOAZETIDINE 1 CARBOXAMIDO)PHENYLMETHANAMINIUM 2,2,2 TRIFLUOROACETATE; 1 (4 BOC AMINOMETHYL PHENYLCARBAMOYL) 4 OXOAZETIDINE 2 CARBOXYLIC ACID; 2 [1 (4 BOC AMINOMETHYL PHENYLCARBAMOYL) 4 OXOAZETIDIN 2 YL]ACETIC ACID; 2 [2 [1 (4 BOC AMINOMETHYL PHENYLCARBAMOYL) 4 OXOAZETIDIN 2 YL]ACETAMIDO]ACETIC ACID; 4 (2 CARBOXYMETHYL 4 OXOAZETIDINE 1 CARBOXAMIDO)PHENYLMETHANAMINIUM 2,2,2 TRIFLUOROACETATE; 4 [2 [2 (CARBOXYMETHYLAMINO) 2 OXOETHYL] 4 OXOAZETIDINE 1 CARBOXAMIDO]PHENYLMETHANAMINIUM 2,2,2 TRIFLUOROACETATE; ALPHA1 BETA3 INTEGRIN; AMINE; ARGINYLGLYCYLASPARTIC ACID; AZETIDINONE DERIVATIVE; BENZYL 1 (4 BOC AMINOMETHYL PHENYLCARBAMOYL) 4 OXOAZETIDINE 2 CARBOXYLATE; BENZYL 2 (4 OXO AZETIDIN 2 YL)ACETATE; BENZYL 2 [1 (4 BOC AMINOMETHYL PHENYLCARBAMOYL) 4 OXOAZETIDIN 2 YL)ACETATE; BENZYL 2 [2 [1 (4 BOC AMINOMETHYL PHENYLCARBAMOYL) 4 OXOAZETIDIN 2 YL]ACETAMIDO]ACETATE; BENZYL 4 OXOAZETIDINE 2 CARBOXYLATE; BETA LACTAM DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; FIBRONECTIN; INTEGRIN; TERT BUTYL 2 (4 OXO AZETIDIN 2 YL)ACETATE; TERT BUTYL 2 [1 (4 BOC AMINOMETHYL PHENYLCARBAMOYL) 4 OXOAZETIDIN 2 YL]ACETATE; TERT BUTYL 4 ISOCYANATOBENZYLCARBAMATE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; 2 [1 (4 BOC AMINOMETHYL PHENYLCARBAMOY;) 4 OXOAZETIDIN 2 YL} ACETIC ACID; 2 [2 [1 (4 BOC AMINOMETHYL PHENYLCARBAMOYL) 4 OXOAZETIDIN 2 YL] ACETAMIDO] ACETIC ACID; 4 (2 CARBOXYMETHYL 4 OXOAZETIDINE 1 CARBOXAMIDO) PHENYLMETHANAMINIUM 2,2,2 TRIFLUOROACETATE; 4 [2 [2 (CARBOXYMETHYLAMINO) 2 OXOETHYL] 4 OXOAZETIDINE 1 CARBOXAMIDO] PHENYLMETHANAMINIUM 2,2,2 TRIFLUOROACETATE; AZETIDINONE; BENZYL 2 (4 OXO AZETIDIN 2 YL) ACETATE; BENZYL 2 [1 (4 BOC AMINOMETHYL PHENYLCARABMOYL) 4 OXOAZATIDIN 2 YL] ACETATE; BENZYL 2 [2 [1 (4 BOC AMINOMETHYL PHENYLCARBAMOYL) 4 OXOAZATIDIN 2 YL] ACETIMIDO] ACETATE; INTERCELLULAR ADHESION MOLECULE 1; TERT BUTYL 2 (4 OXO AZETIDIN 2 YL) ACETATE; TERT BUTYL 2 [1 (4 BOC AMINOMETHYL PHENYLCARBAMOYL) 4 OXOAZETIDIN 2 YL] ACETATE; TERT BUTYL 4 ISOCYANOTOBENZYLCARBAMATE; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 5; 2-AZETIDINONE; AZETIDINE DERIVATIVE; BETA LACTAM; LIGAND;

ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CELL ADHESION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; K562 CELL LINE; MOLECULAR RECOGNITION; PROTEIN IMMOBILIZATION; PROTEIN TARGETING; ACYLATION; FLOW CYTOMETRY; IN VITRO STUDY; AGONISTS; CHEMISTRY; METABOLISM; MOLECULARLY TARGETED THERAPY; SYNTHESIS; TUMOR CELL LINE;

AZETIDINES; BETA-LACTAMS; CELL LINE, TUMOR; DRUG DESIGN; HUMANS; INTEGRIN ALPHA5BETA1; INTEGRIN ALPHAVBETA3; LIGANDS; MOLECULAR TARGETED THERAPY;

EID: 84903310756     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.06.041     Document Type: Article

References (45)

1. H. Wolfenson, I. Lavelin, and B. Geiger Dynamic regulation of the structure and functions of integrin adhesions Dev. Cell 24 2013 447 458
2. M. Barczyk, S. Carracedo, and D. Gullberg Integrins Cell Tissue Res. 339 2010 269 280
3. M.A. Arnaout, S.L. Goodman, and J.-P. Xiong Structure and mechanics of integrin-based cell adhesion Curr. Opin. Cell Biol. 19 2007 495 507
4. N.J. Anthis, and I.D. Campbell The tail of integrin activation Trends Biochem. Sci. 36 2011 191 198
5. R. Zaidel-Bar, and B. Geiger The switchable integrin adhesome J. Cell Sci. 123 2010 1385 1388
6. M.A. Arnaout, B. Mahalingam, and J.P. Xiong Integrin structure, allostery, and bidirectional signaling Annu. Rev. Cell Dev. Biol. 21 2005 381 410
7. J.D. Humphries, A. Byron, and M.J. Humphries Integrin ligands at a glance J. Cell Sci. 119 2006 3901 3903
8. F. Ye, C. Kim, and M.H. Ginsberg Molecular mechanism of inside-out integrin regulation J. Thromb. Haemost. 9 Suppl. 1 2011 20 25
9. B.-H. Luo, C.V. Carman, and T.A. Springer Structural basis of integrin regulation and signaling Ann. Rev. Immunol. 25 2007 619 647
10. J. Takagi, and T.A. Springer Integrin activation and structural rearrangement Immunol. Rev. 186 2002 141 163
11. K.R. Legate, S.A. Wicksötrm, and R. Fässler Genetic and cell biological analysis of integrin outside-in signaling Genes Dev. 23 2009 397 418
12. S.L. Goodman, and M. Picard Integrins as therapeutic targets Trends Pharmacol. Sci. 33 2012 405 412
13. R.O. Hynes Integrins: bidirectional, allosteric signaling machines Cell 110 2002 673 687
14. C. Rüegg, and A. Margotti Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis Cell. Mol. Life Sci. 60 2003 1135 1157
15. F. Danhier, A. Le Breton, and V. Préat RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis Mol. Pharm. 9 2012 2961 2973 (and references cited therein)
16. B. Cacciari, and G. Spalluto Non peptidic αvβ3 antagonists: recent developments Curr. Med. Chem. 12 2005 51 70
17. P. Vanderslice, R.J. Biediger, D.G. Woodside, W.S. Brown, S. Khounlo, N.D. Warier, C.W. Gundlach, A.R. Caivano, W.G. Bornmann, D.S. Maxwell, B.W. McIntyre, J.T. Willerson, and R.A.F. Dixon Small molecule agonist of very late antigen-4 (VLA-4) integrin induces progenitor cell adhesion J. Biol. Chem. 288 2013 19414 19428
18. K. Yea, H. Zhang, J. Xie, T.M. Jones, G. Yang, B. Doo Song, and R.A. Lerner Converting stem cells to dendritic cells by agonist antibodies from unbiased morphogenic selections PNAS 110 2013 14966 14971
19. M.A. Schwartz, K. McRoberts, M. Coyner, K.L. Andarawewa, H.F. Frierson Jr., J.M. Sanders, S. Swenson, F. Markland, M.R. Conaway, and D. Theodorescu Integrin agonists as adjuvants in chemotherapy for melanoma Clin. Cancer Res. 14 2008 6193 6197
20. M.H. Faridi, M.M. Altintas, C. Gomez, J.C. Duque, R.I. Vazquez-Padron, and V. Gupta Small molecule agonists of integrin CD11b/CD18 do not induce global conformational changes and are significantly better than activating antibodies in reducing vascular injury Biochim. Biophys. Acta 1830 2013 3696 3710
21. C. Mas-Moruno, F. Rechenmacher, and H. Kessler Cilengitide: the first anti-angiogenic small molecule drug candidate. Design, synthesis and clinical evaluation Anticancer Agents Med. Chem. 10 2010 753 768
22. M.A. Dechantsreiter, E. Planker, B. Matha, E. Lohof, G. Hölzemann, A. Jonczyk, S.L. Goodman, and H. Kessler N-methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists J. Med. Chem. 42 1999 3033 3040
23. L. Belvisi, T. Riccioni, M. Marcellini, L. Vesci, I. Chiarucci, D. Efrati, D. Potenza, C. Scolastico, L. Manzoni, K. Lombardo, M.A. Stasi, A. Orlandi, A. Ciucci, B. Nico, D. Ribatti, G. Giannini, M. Presta, P. Carminati, and C. Pisano Biological and molecular properties of a new αvβ3, αvβ5 integrin antagonist Mol. Cancer. Ther. 4 2005 1670 1680
24. J.M. Aizpurua, J.I. Ganboa, C. Palomo, I. Loinaz, J.I. Miranda, β-Lactams RGD Cyclopeptides Containing Gamma Turns, PCT Int. Appl., WO 2006048473 A1 20060511, 2006.
25. E. Bourguet, J.-L. Banères, J. Parello, X. Lusinchi, J.-P. Girard, and J.-P. Vidal Nonpeptide RGD antagonists: a novel class of mimetics, the 5,8-disubstituted 1-azabicyclo[5.2.0]nonan-2-one lactam Bioorg. Med. Chem. Lett. 13 2003 1561 1564
26. J.M. Aizpurua, J. Oyarbide, X. Fernandez, J.I. Miranda, J.I. Ganboa, S. Avila, J.L. Castrillo, Preparation of Pro-angiogenic β-Lactams Cyclotetrapeptides, Eur. Pat. Appl., EP 2407478 A1 20120118, 2012.
27. N. Xi, S. Arvedson, S. Eisenberg, N. Han, M. Handley, L. Huang, Q. Huang, A. Kiselyov, Q. Liu, Y. Lu, G. Nunez, T. Osslund, D. Powers, A.S. Tasker, L. Wang, T. Xiang, S. Xu, J. Zhang, J. Zhu, R. Kendall, and C. Dominguez N-Aryl-γ-lactams as integrin αvβ3 antagonists Bioorg. Med. Chem. Lett. 14 2004 2905 2909
28. F. Benfatti, G. Cardillo, S. Fabbroni, P. Galzerano, L. Gentilucci, R. Juris, A. Tolomelli, M. Baiula, A. Sparta, and S. Spampinato Synthesis and biological evaluation of non-peptide αvβ3/α5β1 integrin dual antagonists containing 5,6-dihydropyridin-2-one scaffolds Bioorg. Med. Chem. 15 2007 7380 7390
29. A. Tolomelli, M. Baiula, L. Belvisi, A. Viola, L. Gentilucci, S. Troisi, S.D. Dattoli, S. Spampinato, M. Civera, E. Juaristi, and M. Escudero Modulation of alpha(v)beta(3)- and alpha(5)beta(1)-integrin-mediated adhesion by dehydro-beta-amino acids containing peptidomimetics Eur. J. Med. Chem. 66 2013 258 268
30. F. Schumann, A. Müller, M. Koksch, G. Müller, and N. Sewald Are beta-amino acids gamma-turn mimetics? Exploring a new design principle for bioactive cyclopeptides J. Am. Chem. Soc. 122 2000 12009 12010
31. R. Cervellati, P. Galletti, E. Greco, C.E.A. Cocuzza, R. Musumeci, L. Bardini, F. Paolucci, M. Pori, R. Soldati, and D. Giacomini Monocyclic β-lactams as antibacterial agents: facing antioxidant activity of N-methylthio-azetidinones Eur. J. Med. Chem. 60 2013 340 349
32. P. Galletti, and D. Giacomini Monocyclic β-lactams: new structures for new biological activities Curr. Med. Chem. 18 2011 4265 4283
33. 1 integrin ligands ChemMedChem 6 2011 2264 2272
34. K. Wandzik, C. Zahn, K. Dassler, and H. Fuchs Substantial changes of cellular iron homeostasis during megakaryocytic differentiation of K562 cells Dev. Growth Differ. 51 2009 555 565
35. 3: from discovery to efficacious therapeutic target Circ. Res. 112 2013 1189 1200
36. 2-stimulated adhesion of mastocytoma P-815 cells to the Arg-Gly-Asp-enriched fragment of fibronectin Biochem. Pharmacol. 81 2011 866 872
37. J.M. Aizpurua, J.L. Ganboa, C. Palomo, I. Loinaz, J. Oyarbide, X. Fernandez, E. Balentovà, R.M. Fratila, A. Jiménez, J.I. Miranda, A. Laso, S. Avila, and J.L. Castrillo Cyclic RGD β-lactam peptidomimetics induce differential gene expression in human endothelial cells ChemBioChem 12 2011 401 405
38. W. Yang, C.V. Carman, M. Kim, A. Salas, M. Shimaoka, and T.A. Sprinter A small molecule agonist of an integrin, alphaLbeta2 J. Biol. Chem. 281 2006 37904 37912
39. D. Maiguel, M.H. Faridi, C. Wei, Y. Kuwano, K.M. Balla, D. Hernandez, C.J. Barth, G. Lugo, M. Donnelly, A. Nayer, L.F. Moita, S. Schürer, D. Traver, P. Ruiz, R.I. Vazquez-Padron, K. Ley, J. Reiser, and V. Gupta Small molecule-mediated activation of the integrin CD11b/CD18 reduces inflammatory disease Sci. Signal. 4 2011 ra57
40. Y.-S. Liu, C. Zhao, E. Bergbreiter, and D. Romo Simultaneous deprotection and purification of BOC-amines based on ionic resin capture J. Org. Chem. 63 1998 3471 3473
41. J.F. Sanz-Cervera, R. Blasco, J. Piera, M. Cynamon, I. Ibáñez, M. Murguía, and S. Fustero Improved regioselectivity in pyrazole formation through the use of fluorinated alcohols as solvents: synthesis and biological activity of fluorinated tebufenpyrad analogs J. Org. Chem. 74 2009 8988 8996
42. A.P. Kozikowski, Y. Liao, W. Ttickmantel, S. Wang, S. Pshenichkin, A. Surin, C. Thomsen, and J.T. Wroblewski Synthesis and biology of the rigidified glutamate analogue, trans-2-carboxyazetidine-3-acetic acid (t-CAA) Bioorg. Med. Chem. Lett. 6 1996 2559 2564
43. L. Hunàkovà, J. Sedlàk, M. Klobusická, and B. Chorváth Phorbol ester (TPA)-induced differential modulation of cell surface antigens in human pluripotential leukemia (K-562) cell line: effects of protein kinase inhibitors with broad- and PKC selective inhibitory activity Neoplasma 42 1995 249 253
44. A.R. Qasem, C. Bucolo, M. Baiula, A. Spartà, P. Govoni, A. Bedini, D. Fascì, and S. Spampinato Contribution of alpha4beta1 integrin to the antiallergic effect of levocabastine Biochem. Pharmacol. 2008 751 762
45. S.D. Dattoli, R. De Marco, M. Baiula, S. Spampinato, A. Greco, A. Tolomelli, and L. Gentilucci Synthesis and assay of retro-α4β1 integrin-targeting motifs Eur. J. Med. Chem. 73 2014 225 232